PubRank

Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.

PubWeight™: 2.03‹?› | Rank: Top 2%

🔗 View Article (PMID 32114094)

Published in J Thorac Oncol on February 28, 2020

Authors

Sufang Tian1, Weidong Hu2, Li Niu1, Huan Liu1, Haibo Xu3, Shu-Yuan Xiao4

Author Affiliations

1: Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China.
2: Department of Thoracic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China.
3: Department of Radiology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China.
4: Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China; Department of Pathology, University of Chicago Medicine, Chicago, Illinois. Electronic address: syxiao@uchicago.edu.

Associated clinical trials:

Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis | NCT04315480

TOFAcitinib in SARS-CoV2 Pneumonia | NCT04332042

Use of Remote Monitoring for COVID-19 Patient (RPM) | NCT04425720

COVID-19 Pneumonia: Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program (COVISQAR) | NCT04881214

Articles citing this ↘

Pulmonary Pathology of Early Phase 2019 Novel Coronavirus Pneumonia. J Thorac Oncol (2020) 0.75

Coronavirus Disease 2019 or Lung Cancer: A Differential Diagnostic Experience and Management Model From Wuhan. J Thorac Oncol (2020) 0.75

Pathology of 2019 Novel Coronavirus Pneumonia: A Dynamic Disease Process. J Thorac Oncol (2020) 0.75

Articles by these authors ⇆

Characterization of long noncoding RNA and messenger RNA signatures in melanoma tumorigenesis and metastasis. PLoS One (2017) 0.75

Pathology of 2019 Novel Coronavirus Pneumonia: A Dynamic Disease Process. J Thorac Oncol (2020) 0.75